Latest Breaking News On - மரியன் மெரல் டோ ஆராய்ச்சி நிறுவனம் - Page 1 : comparemela.com
SCYNEXIS to Present Commercial Launch Update for
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
SCYNEXIS to Present Commercial Launch Update for BREXAFEMME® (ibrexafungerp tablets)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
SCYNEXIS to Present Commercial Launch Update for
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
citybizlist : New York : Aquestive Therapeutics Appoint Julie Krop, M D , and Marco Taglietti, M D , To Board
citybizlist.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from citybizlist.com Daily Mail and Mail on Sunday newspapers.
Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors
February 09, 2021 07:30 ET | Source: Aquestive Therapeutics, Inc. Aquestive Therapeutics, Inc. Warren, New Jersey, UNITED STATES
WARREN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced the appointment of Julie Krop, M.D., Chief Medical Officer of Freeline Therapeutics (NASDAQ: FRLN), and Marco Taglietti, M.D., Director, President and Chief Executive Officer of SCYNEXIS (NASDAQ: SCYX), to the Board of Directors of the Company effective February 10, 2021. Aquestive also announced the resignation of Douglas K. Bratton from the Board